XML 14 R6.htm IDEA: XBRL DOCUMENT v3.22.2
Consolidated Statements of Equity - USD ($)
$ in Thousands
Total
Total Caladrius Biosciences, Inc. Stockholders' Equity
Series B Convertible Preferred Stock
Common Stock
Additional Paid-in Capital
Accumulated Other Comprehensive Loss
Accumulated Deficit
Treasury Stock
Non- Controlling Interest in Subsidiary
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Preferred stock, shares outstanding     10,000            
Common stock, beginning balance (in shares) at Dec. 31, 2020       19,389,000          
Beginning balance at Dec. 31, 2020 $ 32,242 $ 32,496 $ 0 $ 19 $ 458,748 $ (13) $ (425,550) $ (708) $ (254)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Net loss (13,745) (13,745)         (13,745)    
Unrealized loss on marketable securities (4) (4)       (4)      
Share-based compensation (in shares)       273,000          
Share-based compensation 683 683     683        
Net proceeds from issuance of common stock and warrants (in shares)       39,860,000          
Net proceeds from issuances of common stock 85,479 85,479   $ 41 85,438        
Proceeds from option exercises (in shares)       7,000          
Proceeds from option exercises 24 24     24        
Preferred stock, ending balance (in shares) at Jun. 30, 2021     10,000            
Common stock, ending balance (in shares) at Jun. 30, 2021       59,529,000          
Ending balance at Jun. 30, 2021 104,679 104,933 $ 0 $ 60 544,893 (17) (439,295) (708) (254)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Preferred stock, shares outstanding     10,000            
Common stock, beginning balance (in shares) at Mar. 31, 2021       59,510,000          
Beginning balance at Mar. 31, 2021 110,014 110,268 $ 0 $ 60 544,601 (72) (433,613) (708) (254)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Net loss (5,682) (5,682)         (5,682)    
Unrealized loss on marketable securities 55 55       55      
Share-based compensation 270 270     270        
Net proceeds from issuance of common stock and warrants (in shares)       19,000          
Net proceeds from issuances of common stock 22 22   $ 0 22        
Preferred stock, ending balance (in shares) at Jun. 30, 2021     10,000            
Common stock, ending balance (in shares) at Jun. 30, 2021       59,529,000          
Ending balance at Jun. 30, 2021 $ 104,679 104,933 $ 0 $ 60 544,893 (17) (439,295) (708) (254)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Preferred stock, shares outstanding     10,000            
Preferred stock, shares outstanding 10,000   10,000            
Common stock, beginning balance (in shares) at Dec. 31, 2021 59,789,712     59,801,000          
Beginning balance at Dec. 31, 2021 $ 92,000 92,254 $ 0 $ 60 545,988 (70) (453,016) (708) (254)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Net loss (10,852) (10,852)         (10,852)    
Share-based compensation (in shares)       728,000          
Share-based compensation 960 960   $ 1 959        
Net proceeds from issuance of common stock and warrants (in shares)       65,000          
Net proceeds from issuances of common stock $ 29 29   $ 0 29        
Proceeds from option exercises (in shares) 0                
Preferred stock, ending balance (in shares) at Jun. 30, 2022 10,000   10,000            
Common stock, ending balance (in shares) at Jun. 30, 2022 60,583,249     60,594,000          
Ending balance at Jun. 30, 2022 $ 82,137 82,391 $ 0 $ 61 546,976 (70) (463,868) (708) (254)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Preferred stock, shares outstanding     10,000            
Common stock, beginning balance (in shares) at Mar. 31, 2022       60,544,000          
Beginning balance at Mar. 31, 2022 88,241 88,495 $ 0 $ 61 546,580 (196) (457,242) (708) (254)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Net loss (6,626) (6,626)         (6,626)    
Unrealized loss on marketable securities 126 126       126      
Share-based compensation (in shares)       (15,000)          
Share-based compensation 367 367     367        
Net proceeds from issuance of common stock and warrants (in shares)       65,000          
Net proceeds from issuances of common stock $ 29 29     29        
Preferred stock, ending balance (in shares) at Jun. 30, 2022 10,000   10,000            
Common stock, ending balance (in shares) at Jun. 30, 2022 60,583,249     60,594,000          
Ending balance at Jun. 30, 2022 $ 82,137 $ 82,391 $ 0 $ 61 $ 546,976 $ (70) $ (463,868) $ (708) $ (254)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Preferred stock, shares outstanding 10,000   10,000